

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Dominique Bourel et al.

Entitled: Novel Ig Fractions Having Immunomodulatory Activity

Serial No.: To be assigned

Date Filed: Concurrently

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the present application, Applicant's respectfully requests that the above-identified application be amended as follows:

In the Claims:

In accordance with 37 C.F.R. § 1.121(c) (3), please substitute for pending claims 3, 4, 6-9, 12, 14, 15-23, 25, and 26 with the following clean version of the claims. The changes to these claims are shown explicitly in the attached "Marked Up Version of Claims."

3. (Amended) The fraction as claimed in 1, characterized in that it reacts with a component selected from IgMs, IgG F(ab')2s and the hapten DNP, with a level of enrichment of greater than 40 compared to the activity of the initial polyvalent Igs.

4. (Amended) The fraction as claimed in claim 1, characterized in that it reacts with at least one of the autoantigens selected from myosin, actin, tubulin and myelin basic protein (MBP), with a level of enrichment of greater than 10 compared to the activity of the initial polyvalent Igs.
